As of 2025-01-22, the Relative Valuation of Helix Biopharma Corp (HBP.TO) is (0.02) CAD. This relative valuation is based on P/E multiples. With the latest stock price at 0.90 CAD, the upside of Helix Biopharma Corp based on Relative Valuation is -102.1%.
The range of the Relative Valuation is (0.02) - (0.06) CAD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 0.1x - 0.3x | 0.1x |
| Forward P/E multiples | 0.1x - 0.3x | 0.1x |
| Fair Price | (0.02) - (0.06) | (0.02) |
| Upside | -101.7% - -106.4% | -102.1% |
| Date | P/E |
| 2025-01-20 | -4.88 |
| 2025-01-17 | -4.72 |
| 2025-01-16 | -5.14 |
| 2025-01-13 | -4.72 |
| 2025-01-10 | -4.67 |
| 2025-01-09 | -4.88 |
| 2025-01-07 | -4.72 |
| 2025-01-06 | -4.88 |
| 2025-01-03 | -4.82 |
| 2024-12-31 | -4.67 |
| 2024-12-30 | -4.56 |
| 2024-12-19 | -5.09 |
| 2024-12-18 | -5.24 |
| 2024-12-16 | -4.98 |
| 2024-12-13 | -5.24 |
| 2024-12-11 | -4.56 |
| 2024-12-10 | -4.56 |
| 2024-12-09 | -4.56 |
| 2024-12-06 | -4.93 |
| 2024-12-05 | -4.98 |
| 2024-12-04 | -5.24 |
| 2024-12-03 | -5.24 |
| 2024-12-02 | -4.98 |
| 2024-11-29 | -4.56 |
| 2024-11-28 | -4.35 |
| 2024-11-27 | -4.14 |
| 2024-11-26 | -4.41 |
| 2024-11-25 | -4.30 |
| 2024-11-22 | -4.04 |
| 2024-11-21 | -3.67 |
| 2024-11-20 | -3.67 |
| 2024-11-19 | -3.72 |
| 2024-11-18 | -3.67 |
| 2024-11-15 | -3.57 |
| 2024-11-14 | -3.57 |
| 2024-11-13 | -3.51 |
| 2024-11-12 | -3.67 |
| 2024-11-11 | -3.83 |
| 2024-11-08 | -3.93 |
| 2024-11-07 | -4.20 |
| 2024-11-06 | -2.99 |
| 2024-11-05 | -3.72 |
| 2024-11-04 | -3.99 |
| 2024-11-01 | -4.09 |
| 2024-10-31 | -4.30 |
| 2024-10-29 | -4.72 |
| 2024-10-28 | -5.30 |
| 2024-10-25 | -5.24 |
| 2024-10-24 | -5.93 |
| 2024-10-23 | -5.72 |